Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China · Delayed Price · Currency is CNY 39.84
+0.44 (1.12%)
Jan 23, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Revenue
Hangzhou Biotest Biotech had revenue of 104.79M CNY in the quarter ending September 30, 2025, a decrease of -13.84%. This brings the company's revenue in the last twelve months to 478.69M, down -7.70% year-over-year. In the year 2024, Hangzhou Biotest Biotech had annual revenue of 559.40M with 26.53% growth.
Revenue (ttm)
478.69M
Revenue Growth
-7.70%
P/S Ratio
12.04
Revenue / Employee
793.85K
Employees
603
Market Cap
5.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 559.40M | 117.29M | 26.53% |
| Dec 31, 2023 | 442.11M | -1.46B | -76.75% |
| Dec 31, 2022 | 1.90B | 83.07M | 4.57% |
| Dec 31, 2021 | 1.82B | 952.70M | 110.09% |
| Dec 31, 2020 | 865.37M | 656.53M | 314.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Wuhan Hvsen Biotechnology | 1.67B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| ChemPartner PharmaTech | 1.07B |
| Beijing Bohui Innovation Biotechnology Group | 834.38M |
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 587.04M |